Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 1;30(8):1274-1283.
doi: 10.1093/ibd/izad175.

Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals

Affiliations

Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals

Samuel J Martínez-Domínguez et al. Inflamm Bowel Dis. .

Abstract

Background: Despite classical association between metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity, there is increasing evidence on the development of MASLD in lean individuals. The aim of the study was to assess the prevalence and risk factors of MASLD and significant liver fibrosis in lean participants with inflammatory bowel disease (IBD).

Methods: This was a cross-sectional, case-control study including 300 lean cases with IBD and 80 lean controls without IBD, matched by sex and age. All participants underwent a liver ultrasound, transient elastography, and laboratory tests.

Results: The lean IBD group showed a significantly higher prevalence of MASLD compared with lean non-IBD group (21.3% vs 10%; P = .022), but no differences were observed in the prevalence of significant liver fibrosis (4.7% vs 0.0%; P = 1.000). No differences were found between the prevalence of MASLD in IBD and non-IBD participants who were overweight/obese (66.8% vs 70.8%; P = .442). In addition, the prevalence of MASLD was significantly higher in the overweight/obese IBD group compared with the lean IBD group (P < .001). IBD was an independent risk factor for MASLD in lean participants (odds ratio [OR], 2.71; 95% confidence interval [CI], 1.05-7.01; P = .04), after adjusting for classic metabolic risk factors and prior history of systemic steroid use. Nevertheless, no association between IBD related factors and MASLD was identified in lean IBD participants. When the overweight/obese and lean IBD groups with MASLD were compared, the overweight/obese IBD group with MASLD showed higher levels of the homeostatic model assessment of insulin resistance (OR, 1.49; 95% CI, 1.11-1.98; P = .007) and history of smoking (OR, 4.66; 95% CI, 1.17-18.49; P = .029).

Conclusions: MASLD prevalence was higher in the lean IBD group compared with lean non-IBD group, independent of classic metabolic risk factors.

Keywords: Crohn’s disease; inflammatory bowel disease; lean MASLD; liver fibrosis; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Graphical Abstract
Graphical Abstract
Figure 1.
Figure 1.
Flowchart of participant selection: (A) cases, (B) controls. BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; IBD, inflammatory bowel disease.
Figure 2.
Figure 2.
Prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD) in cases and controls according to body mass index (BMI) status. Blue bars: cases (inflammatory bowel disease). Red bars: controls (non–inflammatory bowel disease). P values in bold indicate statistical significance (P < .05).
Figure 3.
Figure 3.
Prevalence of significant liver fibrosis in participants with metabolic dysfunction–associated steatotic liver disease according to body mass index (BMI) status. Blue bars: cases (inflammatory bowel disease). Red bars: controls (non-IBD).
Figure 4.
Figure 4.
Logistic regression analysis of metabolic dysfunction–associated steatotic liver disease risk factors in lean participants. Data are presented as odds ratio (OR) and 95% confidence interval (CI). Data were adjusted by sex, age, body mass index (BMI), waist-to-hip ratio, arterial hypertension, type 2 diabetes mellitus (DM), insulin resistance, smoking habit, lipid-lowering drugs use, and previous steroid use. IBD, inflammatory bowel disease.
Figure 5.
Figure 5.
Logistic regression analysis of metabolic dysfunction–associated steatotic liver disease risk factors in the lean inflammatory bowel disease (IBD) group. Data are presented as odds ratio (OR) and 95% confidence interval (CI). Data were adjusted by sex, age, body mass index (BMI), waist-to-hip ratio, arterial hypertension, type 2 diabetes mellitus (DM), insulin resistance, smoking habit, lipid-lowering drugs use, and previous steroid use.

Similar articles

Cited by

References

    1. Riazi K, Azhari H, Charette JH, et al.The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-861. - PubMed
    1. Burra P, Becchetti C, Germani G.. NAFLD and liver transplantation: disease burden, current management and future challenges. JHEP Rep. 2020;2(6):100192. - PMC - PubMed
    1. Lazarus JV, Mark HE, Anstee QM, et al.; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):60-78. - PubMed
    1. Sanyal AJ, Van Natta ML, Clark J, et al.; NASH Clinical Research Network (CRN). Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385(17):1559-1569. - PMC - PubMed
    1. Younossi Z, Stepanova M, Ong JP, et al.; Global Nonalcoholic Steatohepatitis Council. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748-755.e3. - PubMed

Publication types

MeSH terms